View Filing Data

Disclosure of subsidiaries [abstract]

Finance Lease Receivable

15.

FINANCE LEASE RECEIVABLE

In November 2019, the Group subleased one of its leased office spaces in its entirety. The sublease runs for the remaining term of the original lease, until October 2021. The sublease has been classified as a finance lease receivable

Finance lease receivable	31 Dec 2019		1 Jan 2019
	$000		$000
Current		142		-
Non-current		149		-
		292		-

The undiscounted lease payments to be received over the next 5 years are as follows:

	1 Year		2 years		3 or more years
	$000		$000		£000
Undiscounted lease payments receivable		149		150		-
		149		150		-

During the year ending December 31 2019, the Group received $34k of income from its subleasing activities.

Finance Lease Receivable	31 December 2019
	$000
Finance Lease receivable as at 1 Nov 2018		327
Sublease income		(36	)
		292

Investments in Subsidiaries

12 Months Ended

Dec. 31, 2019

INVESTMENTS IN SUBSIDIARIES

16.

INVESTMENTS IN SUBSIDIARIES

The company's interest in subsidiary undertakings is as follows:

Name	Principal activity	Registered Address	Percentage shareholding			Country of incorporation
Tiziana Pharma Limited	Clinical stage biotechnology company	3^rdFloor, 11-12 St James's Square, London, SW1Y 4LB		100	%	England & Wales
Tiziana Therapeutics, Inc.	Clinical stage biotechnology company	420 Lexington Avenue Suite 2525 New York, NY 10170		100	%	USA
Longevia Genomics SRL	Biotech Discovery Company	Via Constantinpoli 42 09100-Cagliari (CA)		100	%	Italy

Tiziana Therapeutics, Inc. was incorporated on 28 October 2015. This entity was set up to house the company's US operations.

Longevia Genomics SRL was incorporated on 4 July 2016. This entity was established to enable the company to carry out R&D activities in Sardinia.

Share Capital

12 Months Ended

Dec. 31, 2019

Disclosure of classes of share capital [abstract]

SHARE CAPITAL

17.

SHARE CAPITAL

Company and Group

	2019		2018		2019		2018		2019		2018
	Ordinary Shares				Deferred Shares				$000
In issue at 1 January		136,463,818		125,054,805		-		-		8,592		8,141
Issued for cash		-		7,742,167		-		-		-		311
Issued in lieu of consultancy fees		190,698		-		-		-		7		-
Conversion of Convertible Loan notes		-		-		-		-		-		-
Conversion of warrants		-		1,454,644		-		-		-		56
Conversion of Loan		-		2,137,625						-		82
In lieu of commission		-		74,577		-		-		-		2
In issue at 31 December		136,654,516		136,463,818		-		-		8,599		8,592

Ordinary Shares

Ordinary shares have a par value of £0.03. They entitle the holder to participate in dividends, and to share in the proceeds of winding up the company in proportion to the number of and amounts paid on the shares held. On a show of hands every holder of ordinary shares present at a meeting in person or by proxy, is entitled to one vote, and upon a poll each share is entitled to one vote. The company does not have a limited amount of authorized capital.

Issuance of ordinary shares

In November 2019, 190,968 new ordinary shares were issued in lieu of a consultancy fee of $105,000.

Share Based Payments

12 Months Ended

Dec. 31, 2019

Share Based Payments [Abstract]

SHARE BASED PAYMENTS

18.

SHARE BASED PAYMENTS

Group and Company Options

The company operates share-based payment arrangements to remunerate directors and key employees in the form of a share option scheme. The exercise price of the option is normally equal to the market price of an ordinary share in the company at the date of grant.

	2019						2018						2017
	Weighted						Weighted						Weighted
	Average exercise price (cents)			Options ('000)			Average exercise price (cents)			Options ('000)			Average exercise price (cents)			Options ('000)

Outstanding at 1 January		107			18,617			125			10,717			90			12,449
Granted		-			-			104			9,500			216			668
Forfeited		(152	)		(2,238	)		(219	)		(1,600	)		(20	)		(2,400	)

Outstanding at 31 December		113			16,379			107			18,617			125			10,717

Exercisable at 31 December		67			5,521			50			5,236			57			5,011

No options were exercised during the years ended 31st December 2019, 2018 and 2017.

The total outstanding fair value of the share option instruments is deemed to be approximately $5,011k as at December 31, 2019 (2018: $6,591k; 2017: $6,217k).

The Directors have used the Black-Scholes option pricing model to estimate the fair value of most of the options applying the assumptions below.

Historical volatility relies in part on the historical volatility of a group of peer companies that management believes is generally comparable to the company.

The company has not paid any dividends on common stock since its inception and does not anticipate paying dividends on its common stock in the foreseeable future.

The company has estimated a forfeiture rate of zero.

	30 April 2018			30 August 2017			10 March 2017

Grant date share price	$	1.041		$	2.156		$	2.331
Exercise share price	$	1.041		$	2.156		$	2.331
Vesting periods		Yr1, Yr 2, Yr 3, Yr4			Yr 1, Yr 2, Yr 3, Yr4			Yr1, Yr 2, Yr 3, Yr4

Risk free rate		0.69% to 1.03	%		0.69% to 1.09	%		0.38% to 1.09	%
Expected volatility		58% to 60	%		58% to 60	%		80% to 167	%
Option life		10 years			10 years			10 years
Weighted average share price	$	1.041		$	2.156		$	2.331
Weighted average fair value per share option	$	0.484		$	0.770		$	1.433

For the options issued with a market condition attached, the Directors have used the Monte Carlo simulation to estimate the fair value of these options, the company uses the following methods to determine its underlying assumptions:

	●	expected volatilities are based on the historical volatilities of the market

	●	the expected term of the awards is 15 years based on managements' assessment of when the market condition is likely to be achieved

	●	a range of fair values per share were produced and management have determined the most appropriate value based on their knowledge of the market and vesting conditions being fulfilled.

Warrants

On March 2, 2015, warrants were granted over 600,000 shares at an exercise price of $0.74 per share in lieu of the issue of options. The warrants are exercisable until December 31, 2021.

On May 31, 2015, warrants were granted over 292,500 shares at an exercise price of $0.97 per share in lieu of fundraising fees. The warrants are exercisable until May 31, 2022.

On November 11, 2017, warrants were granted over 100,000 shares at an exercise price of $2.16 per share in conjunction with a Convertible Loan Note. The warrants are exercisable until November 20, 2022.

On December 11, 2017, warrants were granted over 183,333 shares at an exercise price of $2.16 per share in conjunction with a Convertible Loan Note. The warrants are exercisable until December 11, 2023.

On December 15, 2017, warrants were granted over 196,667 shares at an exercise price of $2.16 per share in conjunction with a Convertible Loan Note. The warrants are exercisable until December 15, 2023.

On January 16, 2018, warrants were granted over 63,334 shares at an exercise price of $2.046 per share in lieu of fundraising fees. The warrants are exercisable until January 15, 2024.

On January 22, 2018, warrants were granted over 133,333 shares at an exercise price of $2.04 per share in conjunction with a Convertible Loan Note. The warrants are exercisable until January 22, 2024.

On March 5, 2018, warrants were granted over 78,000 shares at an exercise price of $2.04 per share in lieu of fundraising fees. The warrants are exercisable until March 5, 2024.

On April 19, 2018, warrants were granted over 51,563 shares at an exercise price of $1.02 per share in lieu of fundraising fees. The warrants are exercisable until April 19, 2024.

On November 28, 2018, warrants were granted over 185,000 shares at an exercise price of $1.02 per share in lieu connection with the issuance and conversion of a loan. The warrants are exercisable until November 27, 2023.

On November 28, 2018, warrants were granted over 150,000 shares at an exercise price of $1.02 per share in connection with the issuance and conversion of a loan. The warrants are exercisable until November 27, 2023.

On October 31, 2019, warrants were granted over 185,950 shares at an exercise price of $0.55 per share in in lieu of fundraising fees. The warrants are exercisable until 31 October 2024.

On October 31, 2019, warrants were granted over 1,289,372 shares at an exercise price of $0.55 per share in connection with the issuance of a convertible loan note. The warrants are exercisable until October 31, 2024.

As disclosed in Note 3, the Group has made an adjustment to its accounting treatment of warrants this year.

The Directors have estimated the fair value of the warrants in services provided using the Black-Scholes valuation model and assumptions above.

For each set of warrants, the charge has been expensed over the service period. A share based payment charge for the year of $nil (year to December 2018, restated: $59k) has been expensed in the statement of comprehensive income.

Convertible Debt Instrument

12 Months Ended

Dec. 31, 2019

Convertible Loan Notes [Abstract]

CONVERTIBLE LOAN NOTES

19.

CONVERTIBLE DEBT INSTRUMENT

Group and Company

Planwise Convertible Debt Instrument 2016

From the date of the reverse acquisition a convertible loan note of $247k was in existence as detailed in the Admission Document dated 31 March 2014. Proceeds of the subscriptions for the notes are to be used exclusively to finance the company's on-going working capital requirements. The terms of the loan note are that the loan notes, plus accrued interest at a rate of 4 per cent above Bank of England base rate per annum, will convert into ordinary shares in the company at a price of £0.10 per share at the election of Planwise any time after the second anniversary of the readmission to AIM on 24 April 2014. The company considers this to be a Convertible Debt Instrument as detailed in the policy described at note 2.

Accounting for the convertible debt instrument

The net proceeds received from the issue of the Planwise Convertible Loan Note has been recorded as a debt liability in the balance sheet and the accrued interest charged to the income statement and the debt liability. The liability for the convertible debt instrument is;

Planwise Convertible Loan Note

	Year ended December 31,
	2019		2018		2017
	$000		$000		$000
Convertible loan notes issued		302		290		278
Accrued interest		11		11		12
		313		302		290

Convertible Instruments Classified as Equity

12 Months Ended

Dec. 31, 2019

CONVERTIBLE INSTRUMENTS CLASSIFIED AS EQUITY

20.

CONVERTIBLE INSTRUMENTS CLASSIFIED AS EQUITY

On October 31, 2019, the Company decided to raise convertible equity finance from supportive existing shareholders. $1,850,000 was raised from the issuance of Convertible Loan Notes. The Loan Notes are short term instruments and carry a coupon of 16% per annum and are convertible (together with all accrued interest) into ordinary shares of nominal value £0.03 each in the capital of the Company at a conversion price of 42p, they are not convertible into cash. The Loan Notes are convertible on the third anniversary of the date of issue of the Notes, or at the election of the noteholder on completion of the next non-qualifying equity financing or on the making of a takeover offer for the Company(as defined in the City Code on Takeovers and Mergers), and such election may be made on an immediate basis or conditional on any such takeover offer being declared, or becoming, unconditional.

The warrants issued in connection with the Loan Notes entitle the holders to subscribe for one additional share per conversion share at the same price of 42p. The warrants may be exercised for a period of up to 5 years from their date of issue.

The principal amount of the Convertible Equity Instrument that was recorded as in the convertible loan note reserve prior to conversion is as follows:

	2019
	$000

Par value of cConvertible loan notes issued		1,850
Less: Fair value of warrants issued to note holders		(545	)

		1,305

Accrued interest		52

		1,357

Reserves

12 Months Ended

Dec. 31, 2019

Reserves [Abstract]

RESERVES

21.

RESERVES

The share based payment reserve for warrants represent the value of equity shares which could be issued in future accounting periods if the warrants in issue are exercised.

The share based payment reserve for options represents the value of equity shares which could be issued in future accounting periods if the share based payment options in issue are exercised.

The convertible loan note reserve represents the value of equity shares which could be issued in future accounting periods if the convertible loan notes are converted into equity.

The other reserve was created as a result of the reverse acquisition of Alexander David Investments Plc, which is described in note 2. The reserve is required due to the fact that the reverse acquisition accounting requires the legal parent's equity structure to be shown.

Retained earnings represent the cumulative profits/(losses) of the entity which have not been distributed to shareholders. This reserve has been credited as part of the capital reduction exercise described below.

On the 14 of September 2016 the High Court granted the Company permission to cancel its share premium account and its capital redemption reserve. The order had previously been ratified at the AGM held on 30 June 2016. The £31.1m of distributable reserves arising from this transaction were taken to the capital reduction reserve.

The Company also decided to cancel its merger relief reserve as part of the capital reduction exercise.

The translation reserve represents the unrealised gains or losses from the foreign currency translation of Companies within the Group.

Financial Instruments

12 Months Ended

Dec. 31, 2019

Financial Instruments [Abstract]

FINANCIAL INSTRUMENTS

22.

FINANCIAL INSTRUMENTS

The main risks arising from the Group's financial instruments are liquidity risk, foreign currency risk and credit risk. The directors regularly review and agree policies for managing each of these risks which are summarized below.

Market risk

Market risk encompasses three types of risk, being foreign currency exchange risk, price risk and fair value interest rate risk. The Group policies for managing fair value interest rate risk are considered along with those for managing cash flow interest rate risk and are set out in the subsection entitled "interest rate risk" below. The directors do not consider the Group's exposure to price risk to be significant. The Group's risk management is coordinated by the directors, and focuses on actively securing the Group's short to medium term cash flows by minimizing the exposure to financial markets. The Group does not engage in the trading of financial assets for speculative purposes nor does it write options.

Credit risk

Credit risk is managed on a group basis. Credit risk arises principally from cash and cash equivalents and deposits with banks and financial institutions as well as credit exposure to customers including committed transactions and outstanding receivables. The group reviews its banking arrangements carefully to minimize such risks and currently has no customers and therefore this risk is viewed as minimal. Management monitor loans between members of the group as part of their internal reporting and assess outstanding receivables for ability to be repaid.

Liquidity risk

The group's policy is to regularly monitor current and expected liquidity requirements to ensure that it maintains sufficient reserves of cash to meet its liquidity requirements in the short and long term. The Group ordinarily finances its activities through cash generated from operating activities and private and public offerings of equity and debt securities.

The table below summarizes the maturity profile of the Group's financial liabilities based on contractual undiscounted payments.

	2019
$000	Less than 3 months		3 to 12 months		Total
Trade and other payables		579		3,612		4,191
Related party payables		264		330		596
Total		843		3,942		4,787

Foreign currency risks

The group operates internationally although the majority of its operations are based in the United Kingdom and the majority of assets and liabilities denominated in British Pounds. It therefore is exposed to foreign exchange risk arising from exposure to various currencies primarily the Euro and US Dollar.

Due to the majority of assets being denominated in British Pounds the group has no formal policies for managing foreign currency risks.

Interest rate risk

The Group has limited exposure to interest-rate risk arising from its bank deposits. These deposit accounts are held at variable interest rates based on Allied Irish Bank base rate.

The directors do not consider the impact of possible interest rate changes based on current market conditions to be material to the net result for the year or the equity position at the year-end for the years ended 31 December 2019, 2018 or 2017.

Capital Risk Management

12 Months Ended

Dec. 31, 2019

Capital Risk Management [Abstract]

CAPITAL RISK MANAGEMENT

23.

CAPITAL RISK MANAGEMENT

For the purpose of the Group's capital management, capital includes called up share capital, share premium, share based payment reserve for options, convertible loan note reserve, share based payment reserve for warrants, capital reduction reserve and all other equity reserves attributable to the equity holders of the parent as reflected in the statement of financial position.

The Group adjusts its capital structure in light of changes in economic conditions and expected business demands on capital. In order to maintain or adjust its capital structure, the Group considers whether or not to pay dividends and adjusts the amount of any dividend payments to shareholders. The Group may also return capital to shareholders or issue additional shares.

Trade and Other Payables

12 Months Ended

Dec. 31, 2019

Trade and other payables [abstract]

TRADE AND OTHER PAYABLES

24.

TRADE AND OTHER PAYABLES

	Year ended December 31,
Group	2019		2018		2017
	$000		$000		$000
Trade payables		4,191		3,641		3,738
Accruals		2,206		2,310		683
		6,397		5,951		4,421

Related Party Transactions

12 Months Ended

Dec. 31, 2019

RELATED PARTY TRANSACTIONS

25.

RELATED PARTY TRANSACTIONS

Rasna Therapeutics Inc is a related party as Kunwar Shailubhai, director of our Company, is also a director of Rasna. In addition, Tiziano Lazzaretti, CFO of Tiziana, is also CFO of Rasna. Rasna is also party to a Shared Services agreement with Tiziana whereby the Company is charged for shared services such as the payroll and rent. As of December 31, 2019, $5k was owed to Tiziana Life Sciences PLC.

OKYO Pharma Ltd is a related party as Kunwar Shailubhai, director of our Company, is also a director of OKYO. In addition, Tiziano Lazzaretti, CFO of Tiziana, is also CFO of OKYO. OKYO is also party to a Shared Services agreement with Tiziana whereby the Company is charged for shared services such as the payroll and rent. As of December 31, 2019, $28k was owed to Tiziana Life Sciences PLC in respect of this agreement. OKYO Pharma Ltd has also extended a short term loan facility of $527k to Tiziana with interest payable of 20% per annum, as Tiziana failed to repay the amount owed by the repayment date. In respect of this loan, $264k was due as of December 31, 2019 and $40k was recognized in the Statement of Comprehensive Income during the year ended December 31, 2019 with regards to the interest accrued on the loan.

Gensignia Life Sciences Inc is a related party as Kunwar Shailubhai, director of our Company, is also a director of Gensignia. In addition, Tiziano Lazzaretti, CFO of Tiziana, is also CFO of Gensignia. As of December 31, 2019, $320k was owed to Tiziana Life Sciences PLC.

Planwise Group Limited is a related party as Gabriele Cerrone, Executive Chairman, is considered to have a beneficial interest in the shares and voting rights held Planwise Group Limited. As described in Note 19, the Company has a Convertible Debt Instrument outstanding with Planwise and as of December 31, 2019, Tiziana owed $332k (2018: £310k) with respect to this instrument.

Leases

12 Months Ended

Dec. 31, 2019

Leases [Abstract]

LEASES

26.

LEASES

All leases are accounted for by recognising a right-of-use asset and a lease liability except for:

●

Leases of low value assets; and

●

Leases with a duration of 12 months or less.

IFRS16 was adopted 1 January 2019 without restatement of comparative figures. For an explanation of the transitional requirements that were applied as at I January 2019, see Note 4. The following policies apply subsequent to the date of initial application, 1 January 2019.

The Group has leases for its offices. Each lease is reflected on the balance sheet as a right-of-use asset and a lease liability. The Group does not have any short term leases or leases of low value assets. Variable lease payments which do not depend on an index or a rate (such as lease payments based on a percentage of Group sales) are excluded from the initial measurement of the lease liability and asset. The Group classifies its right-of-use assets in a consistent manner to its property, plant and equipment (see Note 12).

For leases over office buildings and factory premises the Group must keep those properties in a good state of repair and return the properties in their original condition at the end of the lease.

During the course of 2019, the Group sublet one of its office spaces. This has been recognised as a writeback of the associated right of use asset and the recognition of a finance lease receivable for the value of the sublease.

Right-of-use assets	31 Dec 2019
	$000
At 1 January 2019		1,098
Additions		-
Depreciation		(256	)
Finance lease receivable		(328	)
Loss on disposal		(74	)
Foreign exchange movements		(6	)

		433

Lease Liabilities	31 Dec 2019
	$000
At 1 January 2019		1,098
Additions		-
Interest expense		30
Lease payments		(309	)

		820

Lease liabilities are presented in the statement of financial; position as follows:

	31 Dec 2019		1 Jan 2019
	$000		$000
Current		279		260
Non-current		541		839

		820		1,098

The lease liabilities are secured by the related underlying assets. Future minimum lease payments as at 31 December 2019 were as follows:

	Minimum lease payment due
	Within 1 year			1-2 years			2-5 years			Over 5 years		Total
31 December 2019
Lease payments		301			274			295			-		870
Finance Charges		(22	)		(13	)		(15	)		-		(51	)
Net Present Values		279			261			280					820

The total cash outflow for leases in the year to 1 December 2019 was $206,703.

Post Balance Sheet Events - Post 31 December 2019

12 Months Ended

Dec. 31, 2019

Post Balance Sheet Events - Post 31 December 2018 [Abstract]

POST BALANCE SHEET EVENTS - POST 31 DECEMBER 2018

27.

POST BALANCE SHEET EVENTS – POST 31 DECEMBER 2019

On 13 January 2020, the Company announced that its intention to redomicile the Company to Bermuda and its proposed cancellation from AIM.

On 21 January 2020, the Company announced that the appointment of Greg MacRae to the Board of Directors.

On 23 January 2020, the Company announced the filing of a Form F-3 with the Securities Exchange Commission to enable the Company to potentially conduct a future fundraise in the US. A General meeting was subsequently called to seek general authorities to issue shares which would be required in the event that the Company were to utilise the shelf registration.

On 11 March 2020, the Company announced that it is expediting development of TZLS-501, a novel, fully human anti-interleukin-6 receptor (anti-IL6R) monoclonal antibody (mAb) for treatment of patients infected with coronavirus COVID-19 (SARS-CoV-2). Tiziana plans to administer TZLS-501 using a proprietary formulation technology. The Company entered into a world-wide license for composition-of-matter of TZLS-501, a fully human mAb targeting IL-6R, with Novimmune, SA, a Swiss biotechnology company in January 2017.

On 16 March 2020, the Company announced the closing of its underwritten follow-on public offering of American Depositary Shares ("ADSs") on the NASDAQ Global Market. The Company issued 3,333,333 ADSs (representing 16,666,665 new ordinary shares of nominal value £0.03 each in the capital of the Company) at a price to the public of $3.00 per ADS raising gross proceeds of approximately $10 million (before deducting underwriting discount, commissions and offering expenses). Each ADS offered represents five (5) Ordinary Shares (reduced from 10 ordinary shares in a stock split that took place in October 2019. In addition, the Company has granted the underwriters a 45-day option to purchase up to an additional 499,999 ADSs on the same terms and conditions (the "Option"). All ADSs sold in the Offering were offered by the Company. The number of Ordinary Shares represented by ADSs comprised in the Offering (including by way of the exercise of the Option) were within existing shareholder authorities.

On 9 April 2020, the Company announced that it had developed investigational new technology to treat COVID-19 infections, which consists of direct delivery of anti-IL-6 receptor (anti-IL-6R) monoclonal antibodies (mAbs) into the lungs using a handheld inhaler or nebulizer. Development of this novel technology is a step forward toward expediting development of TZLS-501, a fully-human anti-interleukin-6 receptor (anti-IL6R) monoclonal antibody (mAb) for treatment of patients infected with COVID-19 (SARS-CoV-2) coronavirus. The Company believes the technology could also be applicable for use with other FDA approved mAbs and drugs. The Company has submitted a provisional patent application for the delivery technology. At this time, an estimate of the financial effect cannot be determined.

On 15 April 2020 the Company entered into an "At the Market" or "ATM" Sales Agreement with Think Equity (a division of Fordham Financial Management, Inc.) to raise up to US$20m from the sale of ADSs (each representing 5 new ordinary shares).

On 15 April 2020, the Company issued 420,000 new Ordinary Shares of 3 pence each in connection with the exercise of options by a former director granted under the Company's 2014 share option scheme.

On 24 April 2020, the Company issued 6,118,797 new Ordinary Shares of 3 pence each in paid in respect of (i) the conversion of £1,595,322 in face value of its outstanding convertible notes at a conversion price of 42 pence per share (including accrued interest of 16 per cent.); and (ii) the exercise of 1,712,672 warrants at a price of 35 pence per share, yielding £599,435.20 in cash proceeds for the Company and retiring £1,595,322 of indebtedness.

On 6 May, 2020, the Company held a General Meeting and announced that all resolutions had been passed. The resolutions included the grant of options under the Company's long-term incentive plan or US sub-plan (as appropriate) over 9,000,000 Shares to Dr Kunwar Shailubhai, the Company's Chief Executive Officer and Chief Scientific Officer; (b) options over 400,000 Shares to Tiziano Lazzaretti, the Company's Chief Financial Officer; and (c) options over a further 327,000 Shares to other staff members, all at an exercise price of 35p per share and all conditional on the surrender of all existing share options held by those individuals. The resolutions also included the grant by the Company of options over 3,809,403 Shares to Gabriele Cerrone, the Company's Executive Chairman under the Company's long-term incentive plan at an exercise price of 35p per share and conditional on the surrender of all existing share options held by Mr Cerrone.

On 18 May 2020, the Company issued 264,286 ordinary shares of 3 pence each in respect of the exercise of 264,286 warrants at a price of 50 pence per share, yielding £132,143 in cash proceeds for the Company.

On 2 June 2020, the Company issued 1,234,399 ordinary shares in respect of the exercise of 1,234,399 warrants at a price of 39 pence and 50 pence per share, yielding £578,700 in cash proceeds for the Company. The Company also announced that during the calendar month of May, the Company issued a total of 1,743,445 ordinary shares under the Company's ATM sales agreement announced on 15 April 2020 to meet sales of a total of 348,689 ADSs under the ATM sales agreement, totalling gross proceeds of $1,985,004.

The Company does not believe that the recent outbreak of COVID-19 pandemic will have an adverse effect on the Company' operations. Indeed, the Company has raised substantial funds during the pandemic to enable it to expedite development of TZLS-501 as well as other initiatives within its project pipeline.

Financial Commitments

12 Months Ended

Dec. 31, 2019

Financial Commitments [Abstract]

FINANCIAL COMMITMENTS

28.

FINANCIAL COMMITMENTS

The Group's main financial commitments relate to the contractual payments in respect of its licensing agreements. Due to the uncertain nature of scientific research and development and the length of time required to reach commercialisation of the products of this research and development, pre-clinical, clinical and commercial milestone obligations are not detailed until there is a reasonable certainty that the obligation will become payable. Contractual commitments are detailed where amounts are known and certain.

●

Milciclib project research future payments relate to the achievement of clinical milestones or the payment of royalties.

●

Foralumab project – Future payments relate to the achievement of clinical milestones or the payment of royalties. Diligence obligations are payable to BMS/Medarex should the project continue to commercialisation.

The Group also has financial commitments with a realisation bonus due to its Executive Chairman. The Executive Chairman is also eligible to receive two realisation bonuses as follows:

(c)

in the event that, either: (i) the Group raises, in one or a series of transactions, new equity capital in excess of £20,000,000 (after expenses); or (ii) there is a sale, in one or a series of transactions, of all or substantially all of the assets (calculated on the basis of book values) of the Group Companies (or a licence of the same on an exclusive or non-exclusive basis), where the Enterprise Value equals or exceeds £150,000,000; or (iii) there is a change of control where the Enterprise Value equals or exceeds £150,000,000, in which case the Realisation Bonus will be the amount equal to the Enterprise Value multiplied by two and a half (2.5) per cent;

(d)

In addition to the payment of the Realisation Bonus outlined above, in the event that, during this Agreement, either: (i) there is a sale, in one or a series of transactions, of all or substantially all of the assets ( calculated on the basis of book values) of the Group ( or a licence of the same on an exclusive or non-exclusive basis ), where · the Enterprise Value equals or exceeds £300;000,000; or (ii) there is either a change of control where the Enterprise Value equals or exceeds £300,000,000, the Chairman will be entitled to receive an additional Realisation Bonus in the amount equal to the Enterprise Value multiplied by three and a half (3.5) per cent.

The Enterprise Value means: (i) in the case of a change of control resulting in consideration payable to the Group (for example, on a sale of its assets or licensing transaction), the total cash and non-cash consideration received by the Group; or (ii) in the case of a change of control resulting in consideration payable to the shareholders of the ordinary shares in the issued share capital of the Group from time to time, the total cash and non-cash consideration payable to the Shareholders.

Accounting Policies (Policies)

12 Months Ended

Dec. 31, 2019

Accounting Policies [Abstract]

Basis of preparation

Basis of preparation

Going Concern

Going Concern

The Group incurred losses during the year and has net assets at the year end.

The directors do not believe that Brexit will have an impact on the Group's ability to raise funds as it has access to the US market due to its listing on the Nasdaq.

Basis of consolidation

Basis of consolidation

Business combination

Business combination

Segment reporting

Segment reporting

Taxation

Taxation

Foreign currency translation

Foreign currency translation

The financial statements of overseas subsidiary undertakings are translated into US dollars on the following basis:

●

Assets and liabilities at the rate of exchange ruling at the year-end date.

●

Profit and loss account items at the average rate of exchange for the year.

License fees

License fees

Research and development

Research and development

Financial instruments

Financial instruments

A financial instrument is any contract that gives rise to a financial asset of one entity and a financial liability or equity instrument of another entity.

(a) Financial assets, initial recognition and measurement and subsequent measurement

(b) Financial liabilities, initial recognition and measurement and subsequent measurement

Financial liabilities are classified as measured at amortized cost or FVTPL.

The Group's financial liabilities include trade and other payables.

Warrants

Warrants issued by the Group to investors as part of a share subscription are compound financial instruments where the warrant meets the definition of a financial liability.

Investments

Investments

Investments are held as non-current assets and comprise investments in subsidiary undertakings and are stated at cost less provision for any impairment.

Share capital

Share capital

Ordinary shares of the Company are classified as equity.

Property, plant and equipment

Property, plant and equipment

(i) Recognition and measurement

When parts of an item of property, plant and equipment have different useful lives, they are accounted for as separate items (major components) of property, plant and equipment.

(ii) Depreciation

Depreciation is calculated on the depreciable amount, which is the cost of an asset, or other amount substituted for cost, less its residual value.

The estimated useful lives for the current period and the comparative period are as follows.

Fixtures and fittings	5 years
IT and equipment	3 years

Depreciation methods, useful lives and residual values are reviewed at each reporting date. Depreciation is allocated to the operating expenses line of the income statement.

Impairment

Impairment

Impairment of financial assets measured at amortised cost

At each reporting date the Group recognises a loss allowance for expected credit losses on financial assets measured at amortised cost.

General approach

The general approach is applied to the impairment assessment of refundable lease deposits and other refundable lease contributions, restricted cash and cash and cash equivalents.

Simplified approach

The simplified approach is applied to the impairment assessment of trade receivables.

Under the simplified approach the Group always recognises a loss allowance for a financial asset at an amount equal to the lifetime expected credit losses.

Non-financial assets are tested for impairment whenever events or changes in circumstances indicate that the carrying amount may not be recoverable.

Leases

Leases

Fair Value Measurement

Fair Value Measurement

Level 1 - valued using quoted prices in active markets for identical assets

Level 2 - valued by reference to valuation techniques using observable inputs other than quoted prices included within Level 1;

Level 3 - valued by reference to valuation techniques using inputs that are not based on observable market data.

Share based payments

Share based payments

Upon exercise of share options/warrants, the proceeds received are allocated to share capital with any excess being recorded as share premium.

All goods and services received in exchange for the grant of any share based payment are measured at their fair value.

Convertible loan notes

Convertible loan notes

Where there is no option to repay in cash or the Company has the choice of settlement, and the interest rate is fixed

Where the above conditions are not met

Accounting Policies (Tables)

12 Months Ended

Dec. 31, 2019

Accounting Policies [Abstract]

Schedule of estimated useful lives for the current period and the comparative period

Fixtures and fittings	5 years
IT and equipment	3 years

Changes in Accouting Policies and Prior Year Adjustments (Tables)

12 Months Ended

Dec. 31, 2019

Changes in Accouting Policies and Prior Year Adjustments [Abstract]

Schedule of operating lease liabilities and lease payments

	2019 $000
Operating lease commitments disclosed under IAS17 as at 31 December 2018		1,142
Remaining lease commitments discounted using the Group's incremental borrowing rate as at the date of initial application		1,098
Lease Liability recognised as at 1 January 2019		1,098
Of which:
Current lease liabilities		260
Non-current lease liabilities		839

Schedule of right-of-use assets

	31 December 2019		1 January 2019
		$000		$000
Properties		433		1,098
Total right-of-use assets		433		1,098

Schedule of adjustments impacted prior period of impact on financial statements

	1 January 2017			Adjustment			1 January 2017
	$'000			$'000			$'000 (Restated)
Consolidated Balance Sheet (Extract)
Convertible loan note reserve		17,158			(374	)		(16,784	)
Share based payment reserve (warrants)		271			648			919
Retained Earnings		(29,726	)		(274	)		(30,000	)
Total Equity		4,0883			-			4,088	)

	31 December 2017			Adjustment			31 December 2017
	$'000			$'000			$'000 (Restated)
Consolidated Balance Sheet (Extract)
Share Premium		31,284			(725	)		30,559
Share based payment reserve (warrants)		579			885			1,464
Translation reserve		1997			(9	)		1,988
Retained Earnings		(42,613	)		(151	)		(42,764	)
Total Equity		(2,278	)		-			(2,278	)

	31 December 2018			Adjustment			31 December 2018
	$'000			$'000			$'000 (Restated)
Consolidated Balance Sheet (Extract)
Share Premium		40,862			(1,030	)		39,832
Share based payment reserve (warrants)		743			1,131			1,874
Translation reserve		1977			(91	)		1,967
Retained Earnings		50,630	)		(10	)		(50,721	)
Total Equity		519			-			519

	31 December 2018			Adjustment		31 December 2018
	$'000			$'000		$'000 (Restated)
Consolidated Statement of Comprehensive Income (Extract)
Operating Expenses		(4,418	)		60		(4,358	)
Loss before taxation		(9,939	)		60		(9,879	)

Operating Loss (Tables)

12 Months Ended

Dec. 31, 2019

Operating Loss [Abstract]

Schedule of operating loss

Year Ended
December 31,

2019
$'000

2018
$'000

2016
$'000

License fee

553

662

Depreciation of Property, Plant and Equipment

Depreciation (Right-of-use asset)

245

Foreign exchange (gain)/losses

165

967

720

Employees (Tables)

12 Months Ended

Dec. 31, 2019

Employees [Abstract]

Schedule of employees

	Year ended December 31,
	2019 $'000		2018 $'000		2017 $'000
Group
Staff costs comprised:
Directors' salaries (including bonus)		1,145		606		457
Employee's wages, salaries and bonus		696		712		861
Social security costs		609		491		491
Share based payment charge		1,266		539		539
		3,716		2,348		2,348
The average monthly number of employees, including directors, employed by the group during the year was:
Research and Development		5		6		6
Corporate and administration		4		5		5
		9		11		11

Remuneration of Key Management Personnel (Tables)

12 Months Ended

Dec. 31, 2019

Remuneration of Key Management Personnel [Abstract]

Schedule of remuneration of key management personnel

Year ended December 31,
$'000	2019						2018						2017
	Directors fees		Bonus		Salary		Directors fees		Bonus		Salary		Directors fees		Salary

W Simon		48		-		-		51		-		-		49		-
G. Cerrone (1)		102		182		-		124		-		-		86		-
R. Dalla-Favera		3		-		-		26		-		-		26		-
K. Shailubhai (2)		-		210		600		-		105		300		10		286
		153		392		600		201		105		300		171		286

(1)	Gabriele Cerrone's bonus covers the period June 9, 2016 to December 31, 2019

(2)	Kunwar Shailubhai became an employee of the company on May 24, 2017, at which point he ceased to be a non-executive director.

Schedule of share options were granted to directors

	Year ended December 31,
	2019		2018		2017
	Number of options		Number of options		Number of options

G. Cerrone		-		550,000		-
K. Shailubhai		-		6,500,000		400,000
L. Zanbeletti		-		550,000
		-		7,600,000		400,000

Finance Costs (Tables)

12 Months Ended

Dec. 31, 2019

Finance Costs [Abstract]

Schedule of finance costs

	Year ended December 31,
	2019 $'000		2018 $'000		2017 $'000
Group
Finance Income
Finance income received on net investment in lease		1		-		-
Total finance income		1		-		-

Finance Expense
Finance charge accrued on convertible loan notes		61		12		12
Interest expense on lease liabilities		31		-		-
Total finance Expense		92		12		12
Total Finance Cost		92		12		12

Taxation (Tables)

12 Months Ended

Dec. 31, 2019

Taxation [Abstract]

Schedule of taxation

	Year Ended December 31,
	2019 $'000			2018 $'000			2017 $'000
Group
Current year tax (credit)		(661	)		(1,067	)		(489
Adjustments due to prior periods		(28	)		(879	)		(1,423	)
Total tax (credit) for the period		(689	)		(1,945	)		(1,912	)

The tax charge for the year is different from the standard rate of corporation tax in the United Kingdom of 21.49%. The difference can be reconciled as follows:
Loss before taxation		(10,013	)		(9,939	)		(10,628	)
Loss charged at standard rate of corporation tax 19 % (2018: 19%; 2017: 19.25%)		(1,903	)		(1,888	)		(2,046	)
Other timing differences		-			1,104			2,889
Movement in unrecognised deferred tax		(241	)		-			-
Expenses not deductible for taxation		1,727			176			31
Adjustments due to prior periods		(28	)		(879	)		(1,423	)
Research and development claim		(285	)		(459	)		(1,366
Consolidation adjustment in relation to foreign exchange movements		(689	)		-			-
Other timing differences		-			-			3
		(689	)		(1,945	)		(1,912	)

Loss Per Share (Tables)

12 Months Ended

Dec. 31, 2019

Loss Per Share [Abstract]

Schedule of basic loss per share

	Year ended December 31,
	2019			2018 (Restated)			2017

(Loss) attributable to equity holders of the company ($000)		(9,323	)		(7,934	)		(8,716	)
Weighted average number of ordinary shares in issue		136,482,627			127,553,866			106,403,903
Basic loss per share (cents per share)		(6.83	)		(6.22	)		(8.59	)

Property, IT and Equipment (Tables)

12 Months Ended

Dec. 31, 2019

Property IT and Equipment [Abstract]

Schedule of property, IT and equipment

$000	Furniture and fixtures		IT equipment		Total

Cost
At 1 January 2018		15		31		46
Additions		-		-		-
Disposals		-		-		-
At 31 December 2018		15		31		46

Depreciation
At 1 January 2018		3		20		23
Charge in year		6		10		16
At 31 December 2018		9		30		39

Net Book Value as at 31 December 2018		6		1		7

$000	Furniture and fixtures		IT equipment		Total

Cost
At 1 January 2019		15		31		46
Additions		-		4		4
Disposals		-		-		-
At 31 December 2019		15		35		50

Depreciation
At 1 January 2019		9		30		39
Charge in year		3		2		5
At 31 December 2019		12		32		44

Net Book Value as at 31 December 2019		3		3		6

Other Receivables (Tables)

12 Months Ended

Dec. 31, 2019

Other Receivables [Abstract]

Schedule of other receivables

$000	Year ended December 31,
	2019		2018
Group
Other receivables		134		246
Taxation receivable		676		1,019
Related party receivable		324		25
Prepayments		28		42
Other current assets		-		276
		1,162		1,609

Finance Lease Receivable (Tables)

12 Months Ended

Dec. 31, 2019

Schedule of classified a finance lease receivable

Finance lease receivable	31 Dec 2019		1 Jan 2019
	$000		$000
Current		142		-
Non-current		149		-
		292	ss	-

Schedule of undiscounted lease payments

	1 Year		2 years		3 or more years
	$000		$000		£000
Undiscounted lease payments receivable		149		150		-
		149		150		-

Schedule of income from its subleasing activities

Finance Lease Receivable	31 December 2019
	$000
Finance Lease receivable as at 1 Nov 2018		327
Sublease income		(36	)
		292

Investments in Subsidiaries (Tables)

12 Months Ended

Dec. 31, 2019

Disclosure of subsidiaries [abstract]

Schedule of interest in subsidiary undertakings

Name	Principal activity	Registered Address	Percentage shareholding			Country of incorporation
Tiziana Pharma Limited	Clinical stage biotechnology company	3^rdFloor, 11-12 St James's Square, London, SW1Y 4LB		100	%	England & Wales
Tiziana Therapeutics, Inc.	Clinical stage biotechnology company	420 Lexington Avenue Suite 2525 New York, NY 10170		100	%	USA
Longevia Genomics SRL	Biotech Discovery Company	Via Constantinpoli 42 09100-Cagliari (CA)		100	%	Italy

Share Capital (Tables)

12 Months Ended

Dec. 31, 2019

Disclosure of classes of share capital [abstract]

Schedule of share capital

	2019		2018		2019		2018		2019		2018
	Ordinary Shares				Deferred Shares				$000
In issue at 1 January		136,463,818		125,054,805		-		-		8,592		8,141
Issued for cash		-		7,742,167		-		-		-		311
Issued in lieu of consultancy fees		190,698		-		-		-		7		-
Conversion of Convertible Loan notes		-		-		-		-		-		-
Conversion of warrants		-		1,454,644		-		-		-		56
Conversion of Loan		-		2,137,625						-		82
In lieu of commission		-		74,577		-		-		-		2
In issue at 31 December		136,654,516		136,463,818		-		-		8,599		8,592

Share Based Payments (Tables)

12 Months Ended

Dec. 31, 2019

Share Based Payments [Abstract]

Schedule of share-based payment arrangements

	2019						2018						2017
	Weighted						Weighted						Weighted
	Average exercise price (cents)			Options ('000)			Average exercise price (cents)			Options ('000)			Average exercise price (cents)			Options ('000)

Outstanding at 1 January		107			18,617			125			10,717			90			12,449
Granted		-			-			104			9,500			216			668
Forfeited		(152	)		(2,238	)		(219	)		(1,600	)		(20	)		(2,400	)

Outstanding at 31 December		113			16,379			107			18,617			125			10,717

Exercisable at 31 December		67			5,521			50			5,236			57			5,011

Schedule of estimated a forfeiture rate of zero

	30 April 2018			30 August 2017			10 March 2017

Grant date share price	$	1.041		$	2.156		$	2.331
Exercise share price	$	1.041		$	2.156		$	2.331
Vesting periods		Yr1, Yr 2, Yr 3, Yr4			Yr 1, Yr 2, Yr 3, Yr4			Yr1, Yr 2, Yr 3, Yr4

Risk free rate		0.69% to 1.03	%		0.69% to 1.09	%		0.38% to 1.09	%
Expected volatility		58% to 60	%		58% to 60	%		80% to 167	%
Option life		10 years			10 years			10 years
Weighted average share price	$	1.041		$	2.156		$	2.331
Weighted average fair value per share option	$	0.484		$	0.770		$	1.433

Convertible Debt Instrument (Tables)

12 Months Ended

Dec. 31, 2019

Convertible Loan Notes [Abstract]

Schedule of planwise convertible loan note

	Year ended December 31,
	2019		2018		2017
	$000		$000		$000
Convertible loan notes issued		302		290		278
Accrued interest		11		11		12
		313		302		290

Convertible Instruments Classified as Equity (Tables)

12 Months Ended

Dec. 31, 2019

Schedule of convertible loan note reserve

	2019
	$000

Par value of cConvertible loan notes issued		1,850
Less: Fair value of warrants issued to note holders		(545	)

		1,305

Accrued interest		52

		1,357

Financial Instruments (Tables)

12 Months Ended

Dec. 31, 2019

Financial Instruments [Abstract]

Schedule of financial liabilities based on contractual undiscounted payments

	2019
$000	Less than 3 months		3 to 12 months		Total
Trade and other payables		579		3,612		4,191
Related party payables		264		330		596
Total		843		3,942		4,787

Trade and Other Payables (Tables)

12 Months Ended

Dec. 31, 2019

Trade and other payables [abstract]

Schedule of trade and other payables

	Year ended December 31,
Group	2019		2018		2017
	$000		$000		$000
Trade payables		4,191		3,641		3,738
Accruals		2,206		2,310		683
		6,397		5,951		4,421

Leases (Tables)

12 Months Ended

Dec. 31, 2019

Leases [Abstract]

Schedule of Right-of-use assets

Right-of-use assets	31 Dec 2019
	$000
At 1 January 2019		1,098
Additions		-
Depreciation		(256	)
Finance lease receivable		(328	)
Loss on disposal		(74	)
Foreign exchange movements		(6	)

		433

Schedule of lease liabilities

Lease Liabilities	31 Dec 2019
	$000
At 1 January 2019		1,098
Additions		-
Interest expense		30
Lease payments		(309	)

		820

Schedule of lease liabilities in the statement of financial position

	31 Dec 2019		1 Jan 2019
	$000		$000
Current		279		260
Non-current		541		839

		820		1,098

Schedule of future minimum lease liability payments

	Minimum lease payment due
	Within 1 year			1-2 years			2-5 years			Over 5 years		Total
31 December 2019
Lease payments		301			274			295			-		870
Finance Charges		(22	)		(13	)		(15	)		-		(51	)
Net Present Values		279			261			280					820

Accounting Policies (Details)	12 Months Ended
Accounting Policies (Details)	Dec. 31, 2019
Fixtures and fittings [Member]
Statement Line Items [Line Items]
Estimated useful lives	5 years
IT and equipment [Member]
Statement Line Items [Line Items]
Estimated useful lives	3 years

Accounting Policies (Details Textual) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2019 USD ($) Segment	Jan. 02, 2019 USD ($)	Dec. 31, 2018 USD ($)	Dec. 31, 2014 $ / shares
Account Policies (Textual)
Issue of ordinary share capital \| $ / shares				$ 1
Number of segment \| Segment	1
Right of use asset	$ 433
Lease liability	$ 1,098	$ 1,098

Changes in Accouting Policies and Prior Year Adjustments (Details) - USD ($) $ in Thousands	Dec. 31, 2019	Jan. 02, 2019
Changes in Accouting Policies and Prior Year Adjustments [Abstract]
Operating lease commitments disclosed under IAS17 as at 31 December 2018	$ 1,142
Remaining lease commitments discounted using the Group’s incremental borrowing rate as at the date of initial application	1,098
Lease Liability recognised as at 1 January 2019	1,098	$ 1,098
Current lease liabilities	279	260
Non-current lease liabilities	$ 541	$ 839

Changes in Accouting Policies and Prior Year Adjustments (Details 1) £ in Thousands, $ in Thousands	Dec. 31, 2019 USD ($)	Dec. 31, 2019 GBP (£)	Jan. 02, 2019 GBP (£)
Statement Line Items [Line Items]
Total right-of-use assets \| $	$ 433
GBP [Member]
Statement Line Items [Line Items]
Properties		£ 433	£ 1,098
Total right-of-use assets		£ 433	£ 1,098

Changes in Accouting Policies and Prior Year Adjustments (Details 2) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017	Jan. 02, 2017	Dec. 31, 2016
Consolidated Balance Sheet (Extract)
Share Premium	$ 39,931	$ 39,832
Share based payment reserve (warrants)	2,419	1,874
Retained Earnings	(60,044)	(50,721)
Total Equity	(5,514)	519	$ (2,278)		$ 4,088
Consolidated Statement of Comprehensive Income (Extract)
Loss before taxation	$ (10,012)	(9,879)	(10,505)
Previously Reported [Member]
Consolidated Balance Sheet (Extract)
Convertible loan note reserve				$ 17,158
Share Premium		40,862	31,284
Share based payment reserve (warrants)		743	579	271
Translation reserve		1,977	1,997
Retained Earnings		(50,630)	(42,613)	(29,726)
Total Equity		519	(2,278)	(40,883)
Consolidated Statement of Comprehensive Income (Extract)
Operating Expenses		(4,418)
Loss before taxation		(9,939)
Adjustment [Member]
Consolidated Balance Sheet (Extract)
Convertible loan note reserve				(374)
Share Premium		(1,030)	(725)
Share based payment reserve (warrants)		1,131	885	648
Translation reserve		(91)	(9)
Retained Earnings		(10)	(151)	(274)
Total Equity
Consolidated Statement of Comprehensive Income (Extract)
Operating Expenses		60
Loss before taxation		60
Restated [Member]
Consolidated Balance Sheet (Extract)
Convertible loan note reserve				(16,784)
Share Premium		39,832	30,559
Share based payment reserve (warrants)		1,874	1,464	919
Translation reserve		1,967	1,988
Retained Earnings		(50,721)	(42,764)	(30,000)
Total Equity		519	$ (2,278)	$ (4,088)
Consolidated Statement of Comprehensive Income (Extract)
Operating Expenses		(4,358)
Loss before taxation		$ (9,879)

Changes in Accouting Policies and Prior Year Adjustments (Details Textual)	Jan. 02, 2019
Changes in Accouting Policies and Prior Year Adjustments (Textual)
Weighted average lessee’s incremental borrowing rate	3.35%

Operating Loss (Details) - USD ($) $ in Thousands	12 Months Ended
Operating Loss (Details) - USD ($) $ in Thousands	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Operating Loss [Abstract]
License fee	$ 553	$ 662	$ 662
Depreciation of Property, Plant and Equipment	5	13	13
Depreciation (Right-of-use asset)	245
Foreign exchange (gain)/losses	165	(296)	45
Operating Loss	$ 967	$ 720	$ 720

Employees (Details) - USD ($) $ in Thousands	12 Months Ended
Employees (Details) - USD ($) $ in Thousands	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Staff costs comprised:
Directors' salaries	$ 1,145	$ 606	$ 457
Employee’s wages, salaries and bonus	696	712	861
Social security costs	609	491	491
Share based payment charge	1,266	539	539
Employees, total	3,716	2,348	2,348
The average monthly number of employees, including directors, employed by the group during the year was:
Research and Development	5	6	6
Corporate and administration	4	5	5
Total	$ 9	$ 11	$ 11

Remuneration of Key Management Personnel (Details) - USD ($)
$ in Thousands

12 Months Ended

Dec. 31, 2019

Dec. 31, 2018

Dec. 31, 2017

Schedule of remuneration of key management personnel [Abstract]

$ 153

$ 201

$ 171

392

105

Schedule of remuneration of key management personnel [Abstract]

600

300

286

W Simon [Member]

Schedule of remuneration of key management personnel [Abstract]

^[1]

102

124

^[1]

182

Schedule of remuneration of key management personnel [Abstract]

^[1]

R. Dalla-Favera [Member]

Schedule of remuneration of key management personnel [Abstract]

K. Shailubhai [Member]

^[2]

^[2]

210

105